Valo SPAC Presentation Deck
Valo's scalable acceleration model is designed to build a 'supply chain'
of programs as a digitally native therapeutics company
INTERNAL SUPPLY CHAIN
OF PROGRAMS
FOCUS THERAPEUTIC AREAS:
PROGRAMS/INSIGHTS
CARDIOVASCULAR-METABOLIC-RENAL
First clinical program launch expected in 2021¹
ONCOLOGY
Multiple Drug Candidates2 expected in 2021¹
DATA
NEURODEGENERATIVE
Multiple novel preclinical programs expected
in 2021¹
OPAL ACCELERATION FLYWHEEL
DATA
DRUG
DEVELOPMENT
[1] Reflects 2021 goals
Valo [2] "Drug Candidates" are asset programs that are undergoing IND-enabling studies
Phase III Phase II
BIOLOGICAL DISCOVERY
RWE
Diagnosis
Target
Discovery
Opal
PLATFORM
Phasel
Preclinical
Target ID
Lead Opt
THERAPEUTIC DESIGN
COMPUTE
Portfolio designed to
reduce risk and achieve
high value outcomes
Opal designed to enable
scalable activation and
advancement of
programs
The self-reinforcing nature of Opal's flywheel is designed to enable increasing utility with and at scale
2Q21
23View entire presentation